本帖最后由 老马 于 2012-1-13 21:20 编辑 + k. L/ B' X$ S/ t
3 X5 {7 D# E4 l1 L3 j& l. C% K" @爱必妥和阿瓦斯丁的比较. U4 P2 b, A5 o, p$ u
. O7 l7 }, G$ g9 Whttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
2 _; D+ r- Q$ ]8 d/ ` Q3 B$ y1 U+ j
! m. @( h1 g0 Q0 B( S
6 v. c( J# G8 I( S2 B
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/" e6 {+ P0 T* l
==================================================* g' I; d0 @- I2 t, @) {8 r, z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) @$ m4 j* U+ X# g+ ePatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. k, p6 G- S" Y- q& V4 E
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ @& C* V- ?0 ]/ |$ h; {
|